The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
 
Andrea M. Gross
No Relationships to Disclose
 
Pamela Wolters
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Andrea Baldwin
No Relationships to Disclose
 
Eva Dombi
No Relationships to Disclose
 
Michael J. Fisher
No Relationships to Disclose
 
Brian D. Weiss
No Relationships to Disclose
 
AeRang Kim
No Relationships to Disclose
 
Jaishri O'Neill Blakeley
Consulting or Advisory Role - Abbvie
Research Funding - GlaxoSmithKline (Inst); Lilly (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Patricia Whitcomb
No Relationships to Disclose
 
Marielle Holmblad
No Relationships to Disclose
 
Staci Martin
No Relationships to Disclose
 
Marie Claire Roderick
No Relationships to Disclose
 
Scott M. Paul
No Relationships to Disclose
 
Janet Therrien
No Relationships to Disclose
 
Kara Heisey
No Relationships to Disclose
 
Austin Doyle
Patents, Royalties, Other Intellectual Property - University of Maryland School of Medicine
 
Malcolm A. Smith
No Relationships to Disclose
 
John Glod
Research Funding - Adaptimmune
 
Seth M. Steinberg
No Relationships to Disclose
 
Brigitte C. Widemann
No Relationships to Disclose